Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA149951 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:A gene expression signature from peripheral whole blood for stage I lung adenocarcinoma
2025-01-24 | E-GEOD-20189 | ExpressionAtlas
Project description:Transcriptional profiling of Homo sapiens inflammatory skin diseases (whole skin biospies): Psoriasis (Pso), vs Atopic Dermatitis (AD) vs Lichen planus (Li), vs Contact Eczema (KE), vs Healthy control (KO) In recent years, different genes and proteins have been highlighted as potential biomarkers for psoriasis, one of the most common inflammatory skin diseases worldwide. However, most of these markers are not psoriasis-specific but also found in other inflammatory disorders. We performed an unsupervised cluster analysis of gene expression profiles in 150 psoriasis patients and other inflammatory skin diseases (atopic dermatitis, lichen planus, contact eczema, and healthy controls). We identified a cluster of IL-17/TNFα-associated genes specifically expressed in psoriasis, among which IL-36γ was the most outstanding marker. In subsequent immunohistological analyses IL-36γ was confirmed to be expressed in psoriasis lesions only. IL-36γ peripheral blood serum levels were found to be closely associated with disease activity, and they decreased after anti-TNFα-treatment. Furthermore, IL-36γ immunohistochemistry was found to be a helpful marker in the histological differential diagnosis between psoriasis and eczema in diagnostically challenging cases. These features highlight IL-36γ as a valuable biomarker in psoriasis patients, both for diagnostic purposes and measurement of disease activity during the clinical course. Furthermore, IL-36γ might also provide a future drug target, due to its potential amplifier role in TNFα- and IL-17 pathways in psoriatic skin inflammation. In recent years, different genes and proteins have been highlighted as potential biomarkers for psoriasis, one of the most common inflammatory skin diseases worldwide. However, most of these markers are not psoriasis-specific but also found in other inflammatory disorders. We performed an unsupervised cluster analysis of gene expression profiles in 150 psoriasis patients and other inflammatory skin diseases (atopic dermatitis, lichen planus, contact eczema, and healthy controls). We identified a cluster of IL-17/TNFα-associated genes specifically expressed in psoriasis, among which IL-36γ was the most outstanding marker. In subsequent immunohistological analyses IL-36γ was confirmed to be expressed in psoriasis lesions only. IL-36γ peripheral blood serum levels were found to be closely associated with disease activity, and they decreased after anti-TNFα-treatment. Furthermore, IL-36γ immunohistochemistry was found to be a helpful marker in the histological differential diagnosis between psoriasis and eczema in diagnostically challenging cases. These features highlight IL-36γ as a valuable biomarker in psoriasis patients, both for diagnostic purposes and measurement of disease activity during the clinical course. Furthermore, IL-36γ might also provide a future drug target, due to its potential amplifier role in TNFα- and IL-17 pathways in psoriatic skin inflammation.
2014-12-02 | GSE63741 | GEO
Project description:Transcriptomic profiling of peripheral blood mononuclear cells from patients with Parkinson’s disease and control subjects.
| PRJNA128683 | ENA
Project description:In these studies, we used splice variant-specific microarrays manufactured by the ExonHit company ( www.exonhit.com) on the Affymetrix platform. The goal was to identify splice isoforms whose expression is altered in whole blood of early-stage Parkinson’s disease patients compared to healthy and neurodegenerative disease controls. The study included 19 cases of Parkinson’s disease (PD) samples, 4 of multiple system atrophy (MSA), 4 progressive supranuclear palsy (PSP) and 10 healthy controls. Thirteen splice variants were confirmed in quantitative polymerase chain reactions and used to classify blinded samples from Parkinson’s disease patients and controls with 90% accuracy and 94% sensitivity.
2012-12-01 | GSE34287 | GEO
Project description:Transcription profiling by array of human peripheral blood mononuclear cells from patients with peripheral arterial disease
2025-01-24 | E-GEOD-27034 | ExpressionAtlas
Project description:We determine Parkinson’s disease-specific blood biomarker signature using novel data.
2020-08-01 | GSE134949 | GEO
Project description:Blood transcriptomics of drug-naïve sporadic Parkinson’s disease patients
| PRJNA293554 | ENA
Project description:Expression profiling of peripheral blood mononuclear cells isolated from patients piror to undergoing cardiac catheterization Disease: NonStenotic: 17-0711, 17-0889, 17-0920, 17-0810, 17-0985, 17-0948, 17-0933, 17-0929, 17-0828, 17-0813, 17-1068, 17-0842, 17-0967, 17-0750 Disease: Stentotic: 17-0736, 17-0727, 17-0915, 17-0913, 17-0866, 17-1043, 17-1037, 17-0994, 17-0924, 17-0921, 17-0917, 17-0916, 17-0808, 17-0758, 17-0963, 17-0958, 17-0951, 17-0822, 17-0815, 17-1089, 17-1083, 17-1077, 17-0954, 17-1086, 17-1057, 17-0748, 17-0722 biological repeat: 17-0711, 17-0889, 17-0920, 17-0810, 17-0985, 17-0948, 17-0933, 17-0929, 17-0828, 17-0813, 17-1068, 17-0842, 17-0967, 17-0750 biological repeat: 17-0736, 17-0727, 17-0915, 17-0913, 17-0866, 17-1043, 17-1037, 17-0994, 17-0924, 17-0921, 17-0917, 17-0916, 17-0808, 17-0758, 17-0963, 17-0958, 17-0951, 17-0822, 17-0815, 17-1089, 17-1083, 17-1077, 17-0954, 17-1086, 17-1057, 17-0748, 17-0722 Keywords: disease state analysis
2008-10-08 | GSE10195 | GEO
Project description:Alzheimer Disease peripheral blood mononuclear cell expression
| PRJNA94873 | ENA